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Abstract
Transition metal complexes provide a promising avenue for the design of therapeutic and diagnostic
agents, but the limited understanding of their cellular uptake is a roadblock to their effective
application. Here, we examine the mechanism of cellular entry of a luminescent ruthenium(II)
polypyridyl complex, Ru(DIP)2dppz2+ (where DIP = 4,7-diphenyl-1,10-phenanthroline and dppz =
dipyridophenazine), into HeLa cells, with the extent of uptake measured by flow cytometry. No
diminution of cellular uptake is observed under metabolic inhibition with deoxyglucose and
oligomycin, indicating an energy-independent mode of entry. The presence of organic cation
transporter inhibitors also does not significantly alter uptake. However, the cellular internalization
of Ru(DIP)2dppz2+ is sensitive to the membrane potential. Uptake decreases when cells are
depolarized with high potassium buffer and increases when cells are hyperpolarized with
valinomycin. These results support passive diffusion of Ru(DIP)2dppz2+ into the cell.
Transition metal complexes have tremendous potential as diagnostic and therapeutic agents.
They can be exploited for their modularity, reactivity, imaging capabilities, redox chemistry,
and their precisely defined three-dimensional structure. An increasing number of biological
applications have been explored (1–3). Complexes that are currently in clinical use include the
platinum anticancer drugs, radiodiagnostic agents containing 99mTc, and gadolinium(III)
magnetic resonance imaging contrast agents.
In order to design new metal-based drugs more rationally, an understanding of the physiological
processing of metal complexes is required. Though cellular uptake is critical to the success of
a drug or probe, few mechanistic details are known regarding metal complex uptake. Different
entry mechanisms may be preferred depending on the application, as the mode of entry affects
cell-type specificity, the rate of internalization, and the fate of the compound once inside the
cell. For example, entry by diffusion affords broad cell-type specificity, a great advantage in
the use of fluorescent probes for live cell imaging. Conversely, medicinal chemists may seek
to deliver drugs to target organs, taking advantage of tissue-specific transporters (4) or receptors
(5). For each mode of entry, there are also drawbacks. With protein-mediated transport, the
degree of modification of the molecule is limited because transport relies on recognition. With
endocytosis, molecules are often trapped in endosomes and face degradation by lysosomal
enzymes.
Ruthenium(II) polypyridyl complexes are useful for studying cellular uptake due to their facile
synthesis, stability in aqueous solution, and luminescence. Using confocal microscopy and
flow cytometry, we have examined the uptake of a series of dipyridophenazine (dppz)
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complexes of ruthenium (6). Despite its larger size, the lipophilic Ru(DIP)2dppz2+, (where DIP
= 4,7-diphenyl-1,10-phenanthroline), illustrated in Figure 1, accumulates in cells more quickly
than Ru(bpy)2dppz2+ (where bpy = 2,2’-bipyridine) and Ru(phen)2dppz2+ (where phen = 1,10-
phenanthroline). Ru(DIP)2dppz2+ enters cells within an hour at micromolar concentrations,
providing a reasonable time window for uptake experiments. Details of the cellular uptake
mechanism of Ru(DIP)2dppz2+ can then be applied to understanding uptake characteristics of
other structurally similar cationic metal complexes.
The biological activity of ruthenium complexes was first examined by Francis Dwyer in the
1950s, where a full family of tris(polypyridyl) complexes was shown to have bacteriostatic
and anti-viral activities (7). More recently, many ruthenium complexes have been tested for
therapeutic potential (8), and two ruthenium anticancer drugs (NAMI-A and KP1019) have
reached clinical trials (9,10). Cellular uptake of some ruthenium(III) complexes appears to be
mediated by the iron transport protein transferrin. KP1019 (indazolium trans-[tetrachlorobis
(1H-indazole)ruthenate(III)]) binds transferrin with displacement of a chloride ligand, and is
transported into cells with transferrin by receptor-mediated endocytosis (5). Ruthenium
complexes lacking a labile ligand such as chloride are unlikely to be able to enter cells in this
manner and their mechanism of entry has not been established.
Such coordinatively saturated tris(chelate) ruthenium complexes furthermore serve as close
fluorescent analogs of rhodium complexes that we have explored as potential chemotherapeutic
agents (11). These lipophilic, cationic rhodium complexes target single base mismatches in
DNA and selectively inhibit cellular proliferation in mismatch repair-deficient cell lines (3).
The main routes into a cell are endocytosis, active transport, facilitated diffusion, and passive
diffusion. Due to its lipophilicity and positive charge, Ru(DIP)2dppz2+ likely traverses the
membrane in response to the membrane potential, similar to other lipophilic cations such as
tetraphenylphosphonium and rhodamine 123 (12,13). Here, we use chemical tools to elucidate
the cellular uptake mechanism of Ru(DIP)2dppz2+, with the degree of uptake analyzed by flow
cytometry.
EXPERIMENTAL PROCEDURES
Materials
Cell culture reagents, transferrin-AlexaFluor488 conjugate, and To-Pro-3 were purchased from
Invitrogen. Oligomycin, deoxyglucose, and the cation transporter inhibitors were obtained
from Aldrich. Valinomycin was purchased from CalbioChem.
Synthesis of Ru complexes
Ru(DIP)2dppz2+ and Ru(phen)2dppz2+ were synthesized as described previously (6). Briefly,
Ru(DIP)2Cl2 and Ru(phen)2Cl2 were synthesized in an analogous fashion to Ru(bpy)2Cl2
(14). The dipyridophenazine (dppz) ligand was synthesized as previously described (15) and
added to RuL2Cl2 by refluxing in ethanol-water for > 3 h to make Ru(DIP)2dppz2+ and Ru
(phen)2dppz2+. The ethanol was removed by rotary evaporation, resulting in precipitation of
[Ru(DIP)2dppz]Cl2, which was collected by filtration. Ru(phen)2dppz2+ was precipitated as
the hexafluorophosphate salt, then returned to the chloride salt by Sephadex DEAE anion
exchange column. The Ru complexes utilized are racemic mixtures of the two enantiomers.
Cell culture
HeLa cells (ATCC, CCL2) were maintained in minimal essential medium alpha with 10% fetal
bovine serum and 1% penicillin-streptomycin (100×).
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Inductively Coupled Plasma Mass Spectrometric (ICP-MS) detection of Ru
HeLa cells were grown to ~30% confluency in 75 cm2 flasks and incubated with 5 µM Ru
(DIP)2dppz2+ for 1 h at 37 °C in either media with serum or media without serum. The solution
from the serum-free incubation was saved for circular dichroism measurements (described
below). The cells were rinsed with PBS, detached with trypsin, and counted The cells were
isolated by centrifugation and digested in concentrated nitric acid for 1.5 h at 60 °C. The
solution was diluted with Millipore water to 2.0 mL for the incubation with serum and 20.0
mL for the serum-free incubation, adding nitric acid to give 2%. The Ru content was measured
using a Hewlett Packard 4500 ICP-MS. Data are reported as the mean ± the standard deviation
(n = 3).
Assay of enantiomeric preference in Ru uptake
HeLa cells were grown to ~30% confluency in 75 cm2 flasks and incubated with 5 µM Ru
(DIP)2dppz2+ for 1 h at 37 °C in media without serum and phenol red. After incubation, the
media was retrieved from the flask. The Ru complex was purified from the media using a
Waters C18 Sep-Pak. The solution was loaded onto a 1 g Sep-Pak equilibrated with water. The
Sep-Pak was then rinsed with 150 mL water and 15 mL 20/80 CH3CN/H2O with 0.1% TFA.
The Ru complex was eluted with 90/10 CH3CN/H2O with 0.1% TFA and lyophilized. For
circular dichroism (CD) measurements, this isolated complex was dissolved in CH3CN to give
8 µM complex. CD spectra were recorded on an AVIV 62 CD Spectrometer.
Metabolic inhibition
HeLa cells were detached from culture and treated with either 50 mM 2-deoxy-D-glucose and
5 µM oligomycin in PBS (to inhibit cellular metabolism) or 5 mM glucose in PBS for 1 h at
37 °C. Both solutions also contained 2.5 mg/mL bovine serum albumin fraction V (BSAV).
The cells were then rinsed and suspended in either PBS with BSAV for the inhibition cells, or
PBS with BSAV and 5 mM glucose for the control cells. The cells were incubated with 10 mg/
L transferrin- AlexaFluor488 or 5 µM Ru(DIP)2dppz2+ for 1 h at 37 °C. Following incubation,
the transferrin-treated cells were rinsed with PBS and trypsinized to cleave the transferring
receptors from the cell surface (16). The Ru-treated cells were rinsed. The cells were analyzed
by flow cytometry. Ru-treated cells were not trypsinized following incubation, as rinsed cells
and trypsinized cells gave the same mean luminescence in a control experiment: 282 ± 18 for
the rinsed cells and 284 ± 23 for the trypsinized cells, following a 1 h incubation at 37 °C with
5 µM Ru(DIP)2dppz2+.
Temperature dependence of uptake
HeLa cells were detached from culture and washed with Hanks’ balanced salt solution (HBSS)
supplemented with 2.5 mg/mL BSAV. The cells were incubated with 5 µM Ru(DIP)2dppz2+
or Ru(phen)2dppz2+ for 2 h, or 10 mg/L transferrin-Alexa488 for 1 h, in HBSS with BSAV at
4 °C, ambient temperature (20–23 °C), or 37 °C. Transferrin-treated cells were trypsinized
following incubation. The amount of uptake was analyzed by flow cytometry.
Cation transporter inhibition
HeLa cells were detached from culture and washed with buffer (HBSS supplemented with
BSAV), then pre-treated for 20 min with either 1 mM cation transport inhibitor or buffer only.
The cells were then incubated with 5 µM Ru(DIP)2dppz2+ for 1 h at ambient temperature. The
cells were rinsed with buffer and Ru uptake was analyzed by flow cytometry.
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Modulation of membrane potential
HeLa cells were detached from culture and washed three times with either HBSS (containing
5.8 mM K+) or high K+-HBSS (containing 170 mM K+), both supplemented with 2.5 mg/mL
BSAV. Some of the cells in HBSS were pre-treated with 50 µM valinomycin for 30 min at 37
°C. The cells were incubated with 2 µM Ru(DIP)2dppz2+ for 1 h at 37 °C in one of the following
solutions: HBSS, HBSS with valinomycin (to hyperpolarize the cells), or high K+-HBSS (to
depolarize the cells). The solutions also contained BSAV. After incubation, the cells were
rinsed and the extent of uptake was analyzed by flow cytometry.
Flow cytometry
Cells were detached from culture with EDTA (0.48 mM in PBS) and incubated at 1×106 cells/
mL with Ru complex (added from a concentrated DMSO stock) under conditions described
above, then placed on ice. To-Pro-3 was added at 1 µM immediately prior to flow cytometry
analysis to stain dead cells. The fluorescence of ~20,000 cells was measured using a BD FACS
Aria, exciting with the 488 nm laser for Ru and transferrin-AlexaFluor488, and with the 633
nm laser for To-Pro-3. Emission was observed at 600–620 nm for Ru, 515–545 for
AlexaFluor488, and 650–670 nm for To-Pro-3. Cells exhibiting To-Pro-3 fluorescence were
excluded from the data analysis. Fluorescence data is reported as the mean ± the standard
deviation (n = 3).
RESULTS
Strategy to measure uptake
The dipyridophenazine (dppz) complexes of ruthenium serve as light switches for non-aqueous
environments, luminescing only when bound to the hydrophobic regions of membranes,
nucleic acids, and other macromolecules (17,18). If the Ru complex decomposes or ligand
substitution occurs, the resulting complex would no longer luminesce. Additionally the ligands
themselves are not luminescent. Accordingly, the characteristic luminescence indicates that
the complex one inside the cell remains intact. We can use the luminescence of these ruthenium
complexes to track their cellular uptake in both confocal microscopy and flow cytometry
experiments. Confocal imaging confirms that Ru(DIP)2dppz2+ accumulates inside the cell
rather than associating solely at the membrane surface, as seen in Figure 1 and previously
(6). Ruthenium luminescence is observed throughout the cytoplasm, though mostly excluded
from the nucleus. Flow cytometry, on the other hand, enables the rapid measurement of
ruthenium luminescence intensity for multiple cell populations. Using primarily flow
cytometry, we can then explore the cellular uptake mechanism of Ru(DIP)2dppz2+ by
comparing the ruthenium luminescence following different incubation conditions.
ICP-MS measurement of Ru uptake
Inductively coupled plasma mass spectrometry (ICP-MS) measurements were performed to
quantify the amount of Ru taken up by the cell. HeLa cells were treated with 5 µM Ru
(DIP)2dppz2+ for 1 h at 37 °C in media with or without serum. ICP-MS measurements give
26.4 ± 6.3 amol of Ru per cell for the incubation in media with serum, and 677 ± 73 amol per
cell for the serum-free incubation. Assuming an average cell volume of 1.7 pL (19) and that
the complex is evenly distributed throughout this volume, the Ru concentration in the cell is
approximately 16 µM for incubation with serum and 398 µM for the serum-free incubation.
These results indicate substantial concentration of the complex within the cell, with serum
acting to attenuate the effective free ruthenium complex available in solution.
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Enantiomeric preference in uptake
As racemic Ru(DIP)2dppz2+ was used for uptake experiments, we considered whether HeLa
cells preferentially take in one enantiomer over the other. To test for enantioselectivity
associated with uptake, we assayed for enantiomeric enrichment in the supernatant. Following
incubation of Ru(DIP)2dppz2+ with HeLa cells in serum-free media, the Ru complex was
recovered from the media and the circular dichroism (CD) was examined. Serum-free media
was used for the incubation to remove any potential chiral bias created from interaction of the
complex with serum proteins. ICP-MS determination of the Ru content of the cells confirms
that a significant amount of Ru (~3% of the total) was taken in by the cells. Given this depletion,
we estimate that an enantiomeric preference in uptake of 2.5:1 or greater would be detectable
above instrument noise. However, the CD spectra of Ru(DIP)2dppz2+ after incubation with
cells is within the level of the noise. This absence in optical activity indicates that any
enantiomeric preference must be below this limit.
Energy-dependent uptake mechanisms
Certain cellular uptake routes are energy-dependent, such as endocytosis (20) and active
protein transport. These pathways are hindered when cells are incubated at low temperature (4
°C instead of 37 °C) or in ATP-depleted environments (e.g. from metabolic poisons). To
determine whether Ru(DIP)2dppz2+ enters cells by an energy-dependent process, the complex
was incubated with HeLa cells after ATP depletion by deoxyglucose (a glucose analog that
inhibits glycolysis) and oligomycin (an inhibitor of oxidative phosphorylation) (21,22). As
transferrin is internalized by clathrin-mediated endocytosis, fluorescently (AlexaFluor488)
labeled transferrin was used as a positive control. The cellular uptake of Ru(DIP)2dppz2+
remains essentially unchanged when cells are under metabolic inhibition, with a mean
luminescence of 659 ± 12 compared to 675 ± 10 for the cells not treated with deoxyglucose
and oligomycin (Figure 2). Thus Ru(DIP)2dppz2+ appears to enter cells by an energy-
independent process. In contrast, metabolic inhibition dramatically reduces the endocytosis of
transferrin, demonstrated by the large decrease in the mean fluorescence from 3034 ± 52 to
210 ± 5.
The temperature dependence of Ru(DIP)2dppz2+ uptake was also explored. HeLa cells were
incubated with the complex at 4 °C, ambient temperature (20–23 °C), and 37 °C (Figure 3).
The mean Ru luminescence increases with incubation temperature, from 589 ± 17 at 4 °C to
826 ± 71 at 37 °C. Given the lipophilicity of Ru(DIP)2dppz2+, the increase in cellular uptake
with temperature could also be the result of improved solubility in buffer at higher
temperatures. To test this hypothesis, the temperature dependence of uptake was studied for a
similar but more soluble complex, Ru(phen)2dppz2+. In this case, the mean luminescence
remains roughly the same at the different incubation temperatures, 133 ± 10 at 4 °C and 141
± 3 at 37 °C. Transferrin internalization was significantly more sensitive to temperature, with
the mean fluorescence increasing from 480 ± 7 at 4 °C to 4071 ± 167 at 37 °C.
Effect of organic cation transporter inhibitors
Organisms use polyspecific organic cation transporters (OCTs) for the distribution of
endogenous organic cations and the absorption, distribution, and elimination of cationic drugs
and toxins (23). These transporters facilitate the diffusion of structurally diverse compounds.
OCT substrates are typically organic cations and weak bases, though some neutral compounds
and anions are also transported. Expression of the OCTs varies by tissue type. The carnitine
and cation transporter OCTN2 has the most widespread tissue distribution among the OCTs,
and its expression has been detected in some cancer cell lines, including HeLa (24). Numerous
compounds that inhibit OCT-mediated transport have been identified. Procainamide inhibits
across the OCT family (including OCT1–3, OCTN1, and OCTN2). Tetraethylammonium ion
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is translocated by most of the OCTs, while other n-tetraalkylammonium salts inhibit OCT1
and OCT2, and for some OCTN1 (25).
To investigate whether Ru(DIP)2dppz2+ crosses the membrane using an organic cation
transporter, uptake of Ru(DIP)2dppz2+ in the presence of OCT inhibitors was analyzed. HeLa
cells were incubated with 1 mM inhibitor for 20 min before addition of Ru(DIP)2dppz2+ for 1
h. For OCTs, the IC50’s of the inhibitors used are generally less than 1 mM. Procainamide has
an IC50 of < 3 mM and cimetidine <2 mM for OCTN2. As shown in Figure 4, the extent of
uptake was analyzed by flow cytometry. Significantly, the n-tetraalkylammonium salts and
procainamide do not appreciably alter the cellular uptake of Ru(DIP)2dppz2+. Within error,
the cells have a similar mean luminescence intensity. The complex does not appear to use an
organic cation transporter for entry into HeLa cells.
Effect of membrane potential
The plasma membranes of viable cells exhibit a membrane potential (−50 to −70 mV), with
the inside of the cell negative with respect to the outside (26). As Ru(DIP)2dppz2+ carries a
positive charge, uptake may be driven by the potential difference across the cell membrane.
The membrane potential in animal cells depends mainly on the K+ concentration gradient.
Here, the potential was reduced to close to zero by incubating the cells in buffer with potassium
concentration equivalent to that found intracellularly (~170 mM) (27). This high potassium
buffer (K+-HBSS) was created by replacing sodium salts with equimolar potassium salts, while
hyperpolarization of the membrane was achieved by adding valinomycin to low potassium
buffer (HBSS) (28). Valinomycin is a cyclic peptide that selectively shuttles potassium ions
across the membrane down the electrochemical potassium ion gradient, and it increases
themembrane potential by exporting potassium from the cell.
Ru(DIP)2dppz2+ was incubated with HeLa cells for 1 h in either HBSS, HBSS with
valinomycin (hyperpolarizes), or K+-HBSS (depolarizes). The amount of Ru complex uptake
was analyzed by flow cytometry (Figure 5). Depolarization of the plasma membrane reduces
the uptake of Ru(DIP)2dppz2+, decreasing the mean luminescence of the cells from 232 ± 5 to
154 ± 1. Conversely, hyperpolarization of the membrane with valinomycin clearly promotes
Ru complex uptake, increasing the mean luminescence to 428 ± 13. These results indicate that
the positively charged complex is being driven inside the cells at least in part by the membrane
potential.
DISCUSSION
Cellular uptake of small molecules can occur through energy-dependent (endocytosis, active
transport) and energy-independent (facilitated diffusion, passive diffusion) processes.
Metabolic inhibitors deplete the cell of energy, resulting in diminished uptake of molecules
entering by endocytosis and active transport. HeLa cells treated with the metabolic inhibitors
deoxyglucose and oligomycin show greatly reduced uptake (over 10-fold) of fluorescently-
labeled transferrin, which enters cells by endocytosis. On the other hand, deoxyglucose and
oligomycin treatment cause no reduction of Ru(DIP)2dppz2+ cellular uptake, suggesting an
energy-independent mode of entry. In fact, the midpoint of the luminescence intensity profile
increases slightly in cells facing metabolic inhibition, though the mean fluorescence remains
approximately the same. If Ru(DIP)2dppz2+ is actively exported, this efflux would be slowed
under energy depletion and could explain the small increase. In contrast with the metabolic
inhibition data, Ru(DIP)2dppz2+ uptake decreases slightly with lower temperature (4 °C versus
37 °C), consistent with energy-dependent transport. The difference is not as dramatic as for
transferrin, however, whose fluorescence changes 8-fold. Given that Ru(DIP)2dppz2+ is poorly
soluble in buffer, this change may be due to improved solubility with temperature. Accordingly,
a similar but more soluble complex, Ru(phen)2dppz2+, shows constant uptake at different
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temperatures. Low temperature also increases membrane viscosity, via decreased membrane
fluidity, which can impair diffusion through the membrane.
The possible role of an organic cation transporter (OCT) in translocation of Ru(DIP)2dppz2+
across the membrane was also explored. These transporters facilitate the diffusion of
endogenous organic cations as well as a variety of drugs and toxins. Ru(DIP)2dppz2+ uptake
is not significantly altered in cells co-incubated with OCT inhibitors, indicating that the
complex is likely not an OCT substrate. This result is consistent with the large size of Ru
(DIP)2dppz2+ (~20 Å diameter) compared to known OCT substrates.
The cellular uptake of Ru(DIP)2dppz2+ is, however, influenced by the membrane potential.
Consistent with diffusion of a positively charged molecule, uptake increases at higher potential
and decreases at lower potential. That severe metabolic impairment does not discourage
complex uptake is also consistent with diffusion. As both passage through a channel or passive
carrier and diffusion directly through the lipid bilayer are energy-independent and respond to
changes in the membrane potential, other factors must be considered to distinguish between
these two mechanisms. The ability of Ru(DIP)2dppz2+ to enter the cell despite cation
transporter inhibition, its larger size than typical transporter substrates, and its relatively slow
rate of cellular accumulation implicate passive diffusion as the mechanism of entry.
Passive diffusion is less cell-type specific, allows greater freedom for modification of the
complex than transport via membrane proteins, and does not lead to entrapment in endosomes,
as often occurs with endocytosis. As a result, this mechanism of passive diffusion may portend
the broad applicability of metal complexes in different cell types for different intracellular
functions. Certainly these results provide some basis for considering the biological activities
that have already been identified for cationic transition metal complexes (3,7). Significantly,
knowledge of the mechanism of cellular uptake of this ruthenium(II) polypyridyl complex can
now be applied to the design of structurally similar metal complexes for therapeutic and
diagnostic use.
Abbreviations
DIP, 4,7-diphenyl-1,10-phenanthroline; dppz, dipyrido[3,2-a:2’,3’-c]phenazine; phen, 1,10-
phenanthroline; bpy, 2,2’-bipyridine; HBSS, Hanks’ balanced salt solution; PBS, phosphate-
buffered saline; BSAV, bovine serum albumin fraction V; OCT, organic cation transporter;
ICP-MS, inductively coupled plasma mass spectrometry.
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Figure 1.
A luminescent ruthenium probe used to examine metal complex uptake. Top: Chemical
structure of Ru(DIP)2dppz2+. Bottom: HeLa cells incubated with 5 µM Ru(DIP)2dppz2+ for 4
h, imaged by confocal microscopy. Note that the cytoplasm is extensively stained with the Ru
complex. Scale bar is 10 µm.
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Figure 2.
Flow cytometry measuring Ru incorporation used to examine the effect of metabolic inhibition
on Ru(DIP)2dppz2+ cellular uptake. HeLa cells were pretreated for 1 h with 50 mM
deoxyglucose (dGlc) and 5 µM oligomycin, then rinsed and incubated with 5 µM Ru
(DIP)2dppz2+ or 10 mg/L transferrin-AlexaFluor488 (Tf-Alexa488) for 1 h. Cells treated with
inhibitors (red) are compared to control cells (blue). Top: Ru(DIP)2dppz2+ uptake. Bottom:
transferrin-AlexaFluor488 uptake.
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Figure 3.
Effect of incubation temperature on Ru(DIP)2dppz2+ cellular uptake measured by flow
cytometry. HeLa cells were incubated with 5 µM Ru(DIP)2dppz2+ for 2 h at 4 °C, ambient
temperature (20–23 °C), or 37 °C.
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Figure 4.
Effect of organic cation transporter inhibitors on Ru(DIP)2dppz2+ cellular uptake measured by
flow cytometry. HeLa cells were pretreated with 1 Mm inhibitor for 20 min, then 5 µM Ru
(DIP)2dppz2+ was added for 1 h. Each data point is the mean ± the standard deviation of three
samples.
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Figure 5.
Effect of modulating the plasma membrane potential on Ru(DIP)2dppz2+ cellular uptake
determined by flow cytometry. HeLa cells were incubated with 2 µM Ru(DIP)2dppz2+ in
Hanks’ balanced salt solution (HBSS), HBSS with valinomycin (hyperpolarizes), or K+-HBSS
(depolarizes).
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